Oculis Holding AG (OCS) Current Leases (2021 - 2026)
Oculis Holding AG's (OCS) quarterly Current Leases came in at $531233.9 in Q1 2026, up 57.11% year-on-year from $338124.2 in Q1 2025, and down 15.42% quarter-over-quarter from $628087.2 in Q4 2025.
Oculis Holding AG (OCS) Current Leases (2021 - 2026) Analysis & Trends
Oculis Holding AG's Current Leases history runs 6 years deep, the most recent figure standing at $531233.9 for Q1 2026.
- On a quarterly basis, Current Leases rose 57.11% year-over-year to $531233.9 in Q1 2026; TTM through Mar 2026 was $531233.9, a 57.11% increase from a year earlier, with the FY2025 full-year figure at $605476.5, up 69.1% from the prior year.
- Current Leases slipped to $531233.9 in Q1 2026 per OCS's latest filing, from $628087.2 in the prior quarter.
- Across five years, Current Leases topped out at $628087.2 in Q4 2025 and bottomed at $147399.1 in Q4 2022.
- The 5-year median for Current Leases is $359579.4 (2024), against an average of $341289.4.
- Across the five-year window, Current Leases fell 29.58% in 2022 and soared 83.69% in 2024, its largest moves.
- Year by year, Current Leases stood at $147399.1 in 2022, then surged by 33.08% to $196159.7 in 2023, then soared by 83.31% to $359579.4 in 2024, then surged by 74.67% to $628087.2 in 2025, then decreased by 15.42% to $531233.9 in 2026.
- Per Business Quant, the three latest OCS Current Leases figures stand at $531233.9 (Q1 2026), $628087.2 (Q4 2025), and $526296.1 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 531,233.95 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 20.58 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 872,589.03 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 720.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 11.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.61 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 45.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 531,233.95 |
| Dec 31, 2025 | 628,087.24 |
| Sep 30, 2025 | 526,296.11 |
| Jun 30, 2025 | 374,445.97 |
| Mar 31, 2025 | 338,124.16 |
| Dec 31, 2024 | 359,579.38 |
| Sep 30, 2024 | 362,421.07 |
| Jun 30, 2024 | 361,594.47 |
| Mar 31, 2024 | 208,514.18 |
| Dec 31, 2023 | 196,159.68 |
| Sep 30, 2023 | 206,051.77 |
| Jun 30, 2023 | 196,855.07 |
| Dec 31, 2022 | 147,399.11 |
| Dec 31, 2021 | 209,308.90 |